Video
Dr. Goldberg on Options After Developing Resistance to Osimertinib for NSCLC
Author(s):
Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses options for patients with non
Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses options for patients with non—small cell lung cancer (NSCLC) who develop resistance to osimertinib (Tagrisso).
There are several studies looking at MET inhibitors for patients who have MET amplification, explains Goldberg. There are some data that suggest this is promising. It is still in the realm of investigation, but could be something that becomes useful for patients.
Combining EGFR tyrosine kinase inhibitors (TKIs) with other antibodies is a combination strategy that looks promising, Goldberg adds. This has been looked at for several years. It started with data combining afatinib (Gilotrif) with cetuximab (Erbitux), and now has evolved to trials combining osimertinib and necitumumab (Portrazza). These combination studies are something that physicians are keeping their eyes on, as they may benefit patients.
